Big pharma is terrified of what I am doing, but I am bringing greater clarity to the market, says Bass 10 Jul 15
This time a few months ago no-one inside the world of IP would have given Hayman Capital founder and manager Kyle Bass a second thought, unless they were one of his investors. Now, though, his name is on everyone’s lips. Since teaming up with Erich Spangenberg back in the early part of the year to launch the first of what has become a series of IPR petitions aimed at patents owned by pharmaceutical and biotechnology companies, Bass has helped shape the narrative on patent reform in the US and has drawn vociferous condemnation from an entire industry.
Want to read more?
Register to access two of our subscriber-only articles per month
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts
What our customers are saying
Your magazine is great; a timely and eminently worthwhile read.
Mark S Holmes
Chief executive officer
Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email